Roche's Foundation Medicine wins FDA approval for new cancer test
ZURICH: Roche on Monday said its Foundation Medicine unit won U.S. Food and Drug Administration (FDA) approval for a test to help doctors understand the genetic profile of patients' tumors and guide them to effective therapies.
Roche, which owns 58 percent of Foundation, is hoping to use the FoundationOne CDx assay to personalize cancer care, where treatment is better tailored to the specific molecular characteristics of each patient's disease.
(Reporting by John Miller)
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd